Articles > Blood Cancer

  1. Bringing the Patient Voice into Drug Development

    Wanting to make sure the patient voice is heard when it comes to the development of new therapies, The Leukemia & Lymphoma Society (LLS) recently brought a delegation to Washington D.C. to share personal experiences with the U.S. Food & Drug Administration (FDA). Plans for a research study to learn what patients and caregivers are looking for in new treatments were also presented. LLS’s Office of Public Policy knows the importance of pushing for new drug development, but you can...

    Read More
  2. Looking Ahead: LLS Panel Highlights Trends and Advances

    The Leukemia & Lymphoma Society recently brought together a world-renowned panel of thought leaders to discuss the latest advances and insights into blood cancer research and treatment, drug costs and patient access, and patient advocacy and policy. “There’s never a good time to get cancer but this is a phenomenal time to be fighting it,” said Louis J. DeGennaro, president and CEO of The Leukemia & Lymphoma Society (LLS).

    Read More
  3. Leading Researchers, Clinicians, Policy and Drug Development Experts, and Cancer Survivors Convene to Discuss Latest Advances and Challenges in Treating Blood Cancers

    Click here for a comprehensive media toolkit. New York – February 25, 2016 – A panel of world renowned thought leaders from research, clinical practice, policymaking, pharmaceutical industry and patient advocacy convened today to discuss and debate the latest advances and insights into blood cancer research and treatment, drug costs and patient access, and patient advocacy and policy. The roundtable was organized by The Leukemia & Lymphoma Society (LLS), the world's largest volunta...

    Read More
  4. Coming Soon: A Brave New World

    Research is inching us closer to cures for blood cancer every day – among them, therapies that unleash the immune system, reprogramming of T-cells to track down cancer cells, and personalized treatments based on a patient’s genetic make-up. Survival rates for patients with many blood cancers have doubled, tripled and even quadrupled since the early 1960s. Cures for many patients with acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma have been achieved, and the five-year survival ...

    Read More
  5. Seven Insights for Better Nutrition During Cancer Treatment

    In the New Year, you may be looking to turn over a new leaf. One goal may be to improve your nutrition. Many cancer survivors struggle with food issues. In fact, research shows that up to 80 percent of people with a cancer diagnosis are expected to experience malnutrition at some point during treatment. Even before a diagnosis, as many as 40 percent of people with cancer experience unhealthy weight loss. Unhealthy weight loss can lead to decreased response to treatment, delays in treatment, a...

    Read More
  6. Renewed focus on a national initiative to cure cancer

    For more than 66 years The Leukemia & Lymphoma Society (LLS) has dedicated its energy and resources to finding cures for blood cancers, investing more than $1 billion over that time. Last night in his State of the Union address, President Obama appointed Vice President Joe Biden to take the lead in a “moon shot” mission to cure cancer. We at LLS agree the time is right. “It’s personal for everybody,” the Vice President later said in a statement. As Vice President Biden...

    Read More
  7. Huge Win for Cancer Research

    Congress has approved a $2 billion increase in funding for the National Institutes of Health. The 6.6 percent hike -- to $32.1 billion -- is the largest increase in 12 years and it will make an enormous difference in supporting cancer research in the years ahead. The bill includes a $264 million increase in funding for the National Cancer Institute (boosting NCI funding for the year to $5.2 billion – a 5.3% increase) as well as $200 million in funding for a precision medicine initiative ...

    Read More
  8. #ASH15 Day 4: Breakthrough Therapy Designation for Novel Immunotherapy

    Yesterday we learned the exciting news that the FDA has granted Breakthrough Therapy designation for an investigational immunotherapy LLS is supporting through our Therapy Acceleration Program (TAP). The therapy, KTE-C19, being developed by Kite Pharma, is another example of a chimeric antigen receptor (CAR), an approach that genetically engineers patients’ immune T cells and reintroduces them into the body to kill cancer cells. KTE-C19 is crafted by removing patients' T cells and geneti...

    Read More
  9. The First Official Day of #ASH15

    Beat AML is a collaboration launched nearly three years ago by LLS and the Knight Cancer Institute at Oregon Health & Science University (OHSU), to go on the offenensive against acute myeloid leukemia (AML), a blood cancer with a poor prognosis and little change in the standard of care in 40 years. More than a dozen abstracts from the first phase of the initiative will be featured throughout the American Society of Hematology (#ASH15) Annual Meeting in Orlando over the next few days. #...

    Read More
  10. LLS Activates to Accelerate Cures

    The Leukemia & Lymphoma Society (LLS) continually advocates for laws and policies to ensure that patients have access to lifesaving treatments. Our latest win came this summer when the U.S. House of Representatives approved the 21st Century Cures Act. This bill, which is proof of LLS’s impact and would make a big difference for blood cancer patients, is now on Congress’ “to do” list. The House of Representatives finished its work on the 21st Century Cures Act in July, levera...

    Read More